Controlled release pharmaceutical compositions comprising a fumaric acid ester

Abstract

The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.

1 .- 43 . (canceled) 
     
     
         44 . A method of treating psoriasis, psoriatic arthritis, neurodermatitis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, polyarthritis, multiple sclerosis (MS), juvenile-onset diabetes mellitus, Hashimoto's thyroiditis, Grave's disease, SLE (systemic lupus erythematosus), Sjogren's syndrome, Pernicious anemia, Chronic active (lupoid) hepatitis, Rheumatoid arthritis, optic neuritis, radicular pain, pain associated with radiculopathy, neuropathic pain, sciatica/sciatic pain, organ transplantation rejection, sarcoidosis, necrobiosis lipoidica or granuloma annulare, which method comprises administering orally to a patient in need thereof, an effective dosage of a controlled release capsule comprising one or more enteric coating polymers forming an outermost coating of the capsule, wherein the capsule contains coated micro-crystals, wherein the coated micro-crystals comprise
 as an active substance from 10% to 90% w/w of a fumaric acid ester selected from the group consisting of a di-(C 1 -C 5 )alkylester of fumaric acid, a mono-(C 1 -C 5 )alkylester of fumaric acid, and a pharmaceutically acceptable salt thereof;   ethyl cellulose; and   a hydrophilic excipient;   wherein the fumaric acid ester is in the form of micro-crystals, the ethyl cellulose and hydrophilic excipient are present in a coating on the micro-crystals, the ethyl cellulose is 10% to 50% w/w of the coated micro-crystals, and wherein the release of the fumaric acid ester—when subjected to an in vitro dissolution test employing 0.1 N hydrochloric acid as dissolution medium during the first 2 hours of the test and then 0.05 M phosphate buffer pH 6.5 as dissolution medium—is as follows:   within the first 3 hours after start of the test from 15% to 50% w/w of the total amount of the fumaric acid ester contained in the capsule is released.   
     
     
         45 . (canceled) 
     
     
         46 . The method according to  claim 44 , wherein the release of the fumaric acid ester is as follows:
 within the first 4 hours after start of the test from 20% to 70% w/w of the total amount of the fumaric acid ester is released.   
     
     
         47 . The method according to  claim 46 , wherein the release of the fumaric acid ester is as follows:
 within the first 5 hours after start of the test from 30% to 85% w/w of the total amount of the fumaric acid ester is released.   
     
     
         48 . The method according to  claim 47 , wherein the release of the fumaric acid ester is as follows:
 within the first 6 hours after start of the test from 40% to 90% w/w of the total amount of the fumaric acid ester contained in the capsule is released.   
     
     
         49 . The method according to  claim 48 , wherein the release of the fumaric acid ester is as follows:
 within the first 7 hours after start of the test from 70% to 98% w/w of the total amount of the fumaric acid ester contained in the capsule is released.   
     
     
         50 . The method according to  claim 49 , wherein the release of the fumaric acid ester is as follows:
 within the first 9 hours after start of the test from 80% to 99% w/w of the total amount of the fumaric acid ester contained in the capsule is released.   
     
     
         51 . The method according to  claim 44 , wherein the coated micro-crystals comprise from 40% to 60% w/w of the fumaric acid ester, from 15% to 25% w/w ethyl cellulose, and from 2% to 15% w/w of the hydrophilic excipient. 
     
     
         52 . The method according to  claim 44 , wherein the coated micro-crystals comprise from 65% to 80% w/w of the fumaric acid ester, from 10% to 25% w/w ethyl cellulose, and from 2% to 15% w/w of the hydrophilic excipient. 
     
     
         53 . The method according to  claim 52 , wherein the hydrophilic excipient is polyethylene glycol. 
     
     
         54 . The method according to  claim 52 , wherein the hydrophilic excipient is hydroxyl propyl cellulose. 
     
     
         55 . The method according to  claim 44 , wherein the coated micro-crystals comprise from 50% to 90% w/w of the fumaric acid ester. 
     
     
         56 . The method according to  claim 44 , wherein the fumaric acid ester is selected from the group consisting of dimethylfumarate, diethylfumarate, dipropylfumarate, dibutylfumarate, dipentylfumarate, methyl-ethyl-fumarate, methyl-propylfumarate, methyl-butylfumarate, methyl pentylfumarate, monomethylfumarate, monoethylfumarate, monopropylfumarate, monobutylfumarate, monopentylfumarate, and pharmaceutically acceptable salts thereof. 
     
     
         57 . The method according to  claim 44 , wherein the fumaric acid ester is dimethylfumarate. 
     
     
         58 . The method according to  claim 44 , wherein the fumaric acid ester is monomethylfumarate. 
     
     
         59 . The method according to  claim 44 , wherein the amount of the fumaric acid ester in the capsule is from 90 mg to 360 mg. 
     
     
         60 . The method according to  claim 59 , wherein the amount of the fumaric acid ester in the capsule is 90, 120, 180, 240 or 360 mg.